Key advances from these efforts include approved RAR agonists for acute promyelocytic leukemia (tretinoin; synthetic atRA) and fibrodysplasia ossificans progressiva (palovarotene, RARγ agonist), 13-cis retinoic acid (isotretinoin/Accutane), and adapalene for dermatological applications to activate the non-nuclear pathway; bexarotene in cutaneous T cell leukemia (CTCL) to activate rexinoid signaling, and aciretin (mixed mechanism) for psoriasis and discoid lupus. Here, RARA is linked to acute promyelocytic leukemia.